Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Accumulated Depreciation (2020 - 2025)

Gain Therapeutics has reported Accumulated Depreciation over the past 6 years, most recently at $169608.0 for Q3 2025.

  • Quarterly results put Accumulated Depreciation at $169608.0 for Q3 2025, up 39.41% from a year ago — trailing twelve months through Sep 2025 was $169608.0 (up 39.41% YoY), and the annual figure for FY2024 was $123357.0, up 32.93%.
  • Accumulated Depreciation for Q3 2025 was $169608.0 at Gain Therapeutics, up from $159709.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation for GANX hit a ceiling of $169608.0 in Q3 2025 and a floor of $16307.0 in Q1 2021.
  • Median Accumulated Depreciation over the past 5 years was $71933.0 (2023), compared with a mean of $77536.1.
  • Biggest five-year swings in Accumulated Depreciation: soared 119.98% in 2021 and later surged 32.93% in 2024.
  • Gain Therapeutics' Accumulated Depreciation stood at $28389.0 in 2021, then surged by 87.85% to $53329.0 in 2022, then soared by 74.01% to $92797.0 in 2023, then surged by 32.93% to $123357.0 in 2024, then soared by 37.49% to $169608.0 in 2025.
  • The last three reported values for Accumulated Depreciation were $169608.0 (Q3 2025), $159709.0 (Q2 2025), and $136778.0 (Q1 2025) per Business Quant data.